Trafermin is an injectable drug used to treat chronic wounds and ulcerations. It is a form of recombinant human fibroblast growth factor (FGF). It works by promoting the growth of new blood vessels and collagen, the main building blocks of healthy tissue, which helps to close and heal the wound. It also helps to reduce inflammation and improve the environment surrounding the wound. Trafermin is used to help treat diabetic foot ulcers, pressure ulcers, and venous leg ulcers. It is typically given as an injection once a day for up to three weeks in a row.
Trafermin, also known by the brand name Fiblast, is a medication used to promote wound healing. Here's a breakdown of its key aspects:
Function:
- Trafermin is a recombinant human basic fibroblast growth factor (rhbFGF).
- It stimulates the growth of new cells and blood vessels (angiogenesis) which is crucial for healing wounds.
Applications:
- Trafermin is primarily used in Japan as a topical spray to treat:
- Skin ulcers: This can include diabetic foot ulcers and pressure ulcers.
- Periodontitis: An inflammatory gum disease that can damage the jawbone.
- It's currently under investigation for use in other wound-healing applications.
Mechanism of Action:
- Trafermin mimics the natural human basic fibroblast growth factor (bFGF) which plays a key role in various cellular processes involved in wound healing.
- By stimulating the growth of new cells and blood vessels, it accelerates the healing process.
Dosage and Administration:
- Trafermin is typically applied topically to the affected area as a spray, following the doctor's instructions.
Side Effects:
- Trafermin is generally well-tolerated, but some potential side effects include:
- Application site reactions like redness, itching, or burning sensation.
- Systemic side effects like fever or chills are uncommon but can occur.